ArticleACS pharmacology & translational science2026
Cannabinoid 2 Receptor Activation Mitigates High-Fat Diet/Streptozotocin-Induced Nonalcoholic Fatty Liver Disease in Diabetic Mice by Modulation of Oxidative Stress, Inflammation, and Fibrosis.
Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) represents one of the multifactorial complications of type 2 diabetes (T2D). The cannabinoid type 2 receptor (CB2R) plays a role in diabetes and diabetic complications; therefore, the aim of the present study was to investigate the role of β-caryophyllene (BCP), a CB2R agonist, in NAFLD associated with T2D and underlying CB2R-mediated pharmacological and molecular mechanisms. The murine model of T2D was developed by feeding male C57BL/6 J mice a high-fat diet along with streptozotocin (STZ) injections. After developing diabetes, the animals were orally administered BCP (50 mg/kg, p.o.) for 12 weeks. Treatment with BCP reduced the elevation of liver injury markers and inhibited the expression of NADPH oxidase 2 and NADPH oxidase 4, activating Nrf2 signaling and showing liver protective effects and mitigation of oxidative stress. BCP treatment also inhibited hepatic inflammation, as shown by inhibition of NOD-like receptor protein 3 inflammasome activation in T2D mice. Furthermore, treatment with BCP suppressed hepatic fibrosis and endothelial-to-mesenchymal transition by inhibiting transforming growth factor-β/suppressor of mothers against decapentaplegic (Smad) signaling. Taken together, BCP appears to efficiently improve liver function in diabetic mice by suppressing pathologic events of oxidative stress, inflammation, and fibrosis. To reveal the CB2R-dependent mechanism of BCP, the diabetic animals were pretreated with a CB2R antagonist, AM630, which is expected to abrogate the protective effects of BCP. Pretreatment with AM630 abolished the beneficial effects of BCP on hepatic oxidative stress, inflammation, and fibrosis, as well as liver function in T2D mice. These results demonstrate that BCP has the potential to be a novel agent of natural origin from cannabinoids, like compounds, for NAFLD associated with diabetes. The study is suggestive of therapeutic benefits of BCP and could be useful in nutraceutical and pharmaceutical development of BCP and a new in-class agent mediating CB2R activation for NAFLD with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.